Develops next-generation programmed T cell therapies for the treatment of cancer.
Symbol: | AUTL |
---|---|
Quote: | 2.64 |
Change: | -0.04 |
Change %: | -1.49% |
High: | 2.70 |
Low: | 2.58 |
Open: | 2.68 |
---|---|
Volume: | 2,860,384 |
52 Week: | 1.10-5.00 |
P/E Ratio: | -3.00 |
EPS: | -0.88 |
Market Cap: | 702.60 M |
Autolus Therapeutics plc, headquartered in London, United Kingdom, is a dynamic clinical-stage biopharmaceutical company dedicated to advancing innovative T cell therapies for the treatment of cancer. The company's robust pipeline includes several promising programs aimed at harnessing the power of programmed T cells to target various cancers effectively.
Among its clinical-stage programs, Autolus Therapeutics is advancing obecabtagene autoleucel (AUTO1), a CD19-targeting T cell therapy currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in Phase 1 trials for pediatric patients with relapsed or refractory ALL. The company's portfolio also features AUTO4, designed for peripheral T-cell lymphoma, AUTO6NG targeting GD2 for neuroblastoma in preclinical trials, and AUTO8 undergoing Phase I trials for multiple myeloma. Autolus Therapeutics is also actively developing AUTO5, a hematological product candidate in preclinical stages.
Founded in 2014, Autolus Therapeutics has rapidly emerged as a leader in the field of T cell therapies, leveraging cutting-edge research and strategic collaborations to advance its pipeline. With a steadfast commitment to transforming cancer treatment paradigms, the company continues to pioneer novel therapies that hold promise for improving outcomes and quality of life for patients worldwide.
Exchange: | NASDAQ |
---|---|
Beta: | 1.81 |
Industry: | Biotechnology |
Sector: | Healthcare |
Employees: | 647 |
IPO Date: | Jun 22, 2018 |